Article: Cortecs International commences Phase II chronic bronchitis trials with its oral pseudomonas vaccine.

LONDON--(BUSINESS WIRE)--July 24, 1996--Cortecs International (NASDAQ: DLVRY/ LSE:COR / ASX:CRI) has commenced two Phase II trials of its oral Pseudomonas aeruginose therapeutic vaccine (Pseudostat) in patients with chronic bronchitis.

The first trial involves 70 patients with chronic bronchitis whose lungs are colonized (infected) by the bacteria Pseudomonas aeruginosa and Haemophilus influenzae. After a course of oral vaccination in tablet form, patients will be followed up for a total of nine months from the date of the first tablet. Efficacy outcome measures are a reduction of bacterial colonization and reduction of episodes of acute bronchitis. This study is scheduled ...

Related newspaper, magazine, and journal articles:

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!